K2M Group Holdings, Inc., a medical device company, provides spine and minimally invasive solutions in the United States and internationally. The company offers implants, disposables, and instruments primarily to hospitals for use by spine surgeons to treat spinal pathologies, such as deformity, trauma, and tumor. Its complex spine products include EVEREST, MESA, and MESA 2 deformity spinal systems; NILE alternative and proximal fixation spinal systems; MESA rail deformity spinal systems; Cricket spinal correction rod reduction instrumentation; CAPRI corpectomy cage systems; MESA small stature, rail small stature, and mini spinal systems; SERENGETI complex spine minimally invasive retractor systems; RAVINE complex spine lateral access systems; SANTORINI corpectomy cage systems; YUKON OCT spinal systems; and PALO ALTO cervical static corpectomy cage systems. The company's minimally invasive surgery products consist of EVEREST minimally invasive spinal and XT spinal, SERENGETI minimally invasive retractor, MOJAVE PL 3D expandable interbody, RAVINE lateral access, CASCADIA lateral 3D interbody, ALEUTIAN lateral interbody, and TERRA NOVA minimally invasive access systems. In addition, its degenerative spine products comprise EVEREST degenerative spinal, CASCADIA and ALEUTIAN interbody, SAHARA AL expandable stabilization, RHINE cervical disc, CHESAPEAKE interbody, PYRENEES cervical plate, and BLUE RIDGE hybrid cervical plate systems. Further, the company provides Balance ACS, a platform that includes tools to assist surgeons with obtaining authorization from healthcare insurers. K2M Group Holdings, Inc. markets and sells its products through direct sales employees, independent sales agencies, and distributor partners. The company was founded in 2004 and is headquartered in Leesburg, Virginia.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KTWO
Previous Symbol
CUSIPN/A
Phone703-777-3155
Debt
Debt-to-Equity Ratio0.55
Current Ratio3.10
Quick Ratio1.79
Price-To-Earnings
Trailing P/E Ratio-31.61
Forward P/E Ratio-35.71
P/E GrowthN/A
Sales & Book Value
Annual Sales$258.03 million
Price / Sales4.66
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5.59 per share
Price / Book4.92
Profitability
EPS (Most Recent Fiscal Year)($0.87)
Net Income$-37,140,000.00
Net Margins-16.66%
Return on Equity-19.69%
Return on Assets-11.71%
Miscellaneous
Employees484
Outstanding Shares43,740,000
Market Cap$1.20 billion
OptionableOptionable
K2M Group (NASDAQ:KTWO) Frequently Asked Questions
What is K2M Group's stock symbol?
K2M Group trades on the NASDAQ under the ticker symbol "KTWO."
How were K2M Group's earnings last quarter?
K2M Group Holdings Inc (NASDAQ:KTWO) released its quarterly earnings results on Thursday, November, 8th. The medical device company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.20. The medical device company had revenue of $71.36 million for the quarter, compared to analysts' expectations of $71.50 million. K2M Group had a negative net margin of 16.66% and a negative return on equity of 19.69%. View K2M Group's Earnings History.
What price target have analysts set for KTWO?
7 analysts have issued 12-month price targets for K2M Group's stock. Their forecasts range from $25.00 to $29.00. On average, they anticipate K2M Group's stock price to reach $26.80 in the next twelve months. This suggests that the stock has a possible downside of 2.5%. View Analyst Price Targets for K2M Group.
What is the consensus analysts' recommendation for K2M Group?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for K2M Group in the last year. There are currently 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for K2M Group.
What are Wall Street analysts saying about K2M Group stock?
Here are some recent quotes from research analysts about K2M Group stock:
- 1. Needham & Company LLC analysts commented, "SYK announced an agreement to acquire KTWO for $27.50 per share (a 26% premium to KTWO’s closing price on 8/29/18) or ~$1.4B of cash. SYK is paying 4.4x our 2019E KTWO sales vs. its small/mid-cap ortho peers which are trading at a median 2019E EV/sales of 3.8x. Other strategic bidders are unlikely in our view for reasons we detail below. And we do not expect any anti-trust issues since the combined spine business should only have ~12% market share. As a result, we are downgrading KTWO to Hold from Buy." (8/30/2018)
- 2. Cantor Fitzgerald analysts commented, "We believe that KTWO’s outperformance in the US market over the last two years has been underappreciated. We think US momentum should continue in 2018 and beyond, driven by innovative new product launches and sales rep hires. KTWO has been at the forefront of the 3D-printed implant movement and currently has the broadest 3D- printed spine portfolio on the market. This expertise has attracted and should continue to attract new surgeons to KTWO. Additionally, we think KTWO has made smart international distribution changes, which should accelerate OUS growth." (8/30/2018)
- 3. According to Zacks Investment Research, "K2M Group Holdings, Inc. is a global medical device company. The Company is focused on designing, developing and commercializing complex spine and minimally invasive spine technologies and techniques. Its products consist of implants, disposables and instruments which are marketed and sold primarily to hospitals for use by spine surgeons. The Company's products include Complex Spine, Minimally Invasive Spine and Degenerative Spine. Its technologies include MESA, Rail 4D, Deformity Cricket, SERENGETI, RAVINE, EVEREST and tifix. K2M Group Holdings, Inc. is headquartered in Leesburg, Virginia. " (7/4/2018)
Has K2M Group been receiving favorable news coverage?
News headlines about KTWO stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. K2M Group earned a news impact score of 1.4 on InfoTrie's scale. They also gave media coverage about the medical device company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
Who are some of K2M Group's key competitors?
Some companies that are related to K2M Group include ICU Medical (ICUI), Globus Medical (GMED), Penumbra (PEN), Integra Lifesciences (IART), Cantel Medical (CMD), Novocure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Glaukos (GKOS), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Atrion (ATRI), Nevro (NVRO) and Luminex (LMNX).
Who are K2M Group's key executives?
K2M Group's management team includes the folowing people:
- Mr. Eric D. Major, Co-Founder, Chairman, CEO & Pres (Age 48)
- Dr. John Phillip Kostuik, Co-Founder, Chief Medical Officer & Director (Age 80)
- Mr. Gregory S. Cole, Chief Financial Officer (Age 48)
- Mr. Lane E. Major, Chief Operating Officer (Age 39)
- Mr. Dave B. MacDonald, Sr. VP of Operations
Who are K2M Group's major shareholders?
K2M Group's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.25%), JPMorgan Chase & Co. (7.09%), Vanguard Group Inc. (4.73%), Vanguard Group Inc (4.73%), FIL Ltd (3.98%) and Schroder Investment Management Group (3.63%). Company insiders that own K2M Group stock include George Z Moratis, Gregory S Cole and John Philip Md Kostuik. View Institutional Ownership Trends for K2M Group.
Which major investors are selling K2M Group stock?
KTWO stock was sold by a variety of institutional investors in the last quarter, including Penn Capital Management Co. Inc., Emerald Mutual Fund Advisers Trust, Falcon Point Capital LLC, Artemis Investment Management LLP, Bellevue Group AG, Schroder Investment Management Group, Suffolk Capital Management LLC and Blair William & Co. IL. Company insiders that have sold K2M Group company stock in the last year include George Z Moratis and Gregory S Cole. View Insider Buying and Selling for K2M Group.
Which major investors are buying K2M Group stock?
KTWO stock was purchased by a variety of institutional investors in the last quarter, including FIL Ltd, Nuance Investments LLC, Water Island Capital LLC, Gabelli Funds LLC, JPMorgan Chase & Co., Alpine Associates Management Inc., Glazer Capital LLC and GABELLI & Co INVESTMENT ADVISERS INC.. View Insider Buying and Selling for K2M Group.
How do I buy shares of K2M Group?
Shares of KTWO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is K2M Group's stock price today?
One share of KTWO stock can currently be purchased for approximately $27.50.
How big of a company is K2M Group?
K2M Group has a market capitalization of $1.20 billion and generates $258.03 million in revenue each year. The medical device company earns $-37,140,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. K2M Group employs 484 workers across the globe.
What is K2M Group's official website?
How can I contact K2M Group?
K2M Group's mailing address is 600 HOPE PARKWAY SE, LEESBURG VA, 20175. The medical device company can be reached via phone at 703-777-3155 or via email at [email protected]
MarketBeat Community Rating for K2M Group (NASDAQ KTWO)
MarketBeat's community ratings are surveys of what our community members think about K2M Group and other stocks. Vote "Outperform" if you believe KTWO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KTWO will underperform the S&P 500 over the long term. You may vote once every thirty days.
